Mydayis Capsule, Extended Release
Product Images NDC 54092-474

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Mydayis (NDC 54092-474). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Takeda Pharmaceuticals America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Mydayis 01)

FDA Label Image

Figure 2 (Mydayis 02)

FDA Label Image

Principal Display Panel (12.5 mg Capsule Bottle Label)

MYDAYIS is a registered trademark of Takeda Pharmaceuticals USA, Inc. It is a mixed salt formulation of a single-entity amphetamine product. It is an extended-release capsule of 100 capsules to be kept in a tight, light-resistant container. It is crucial not to substitute it with Adderall XR. The Takeda Pharmaceuticals America distributed this product and patented it. The text also provides details of the permissible temperature range for handling the product and the NDC number.*

FDA Label Image

Principal Display Panel (25 mg Capsule Bottle Label)

This appears to be a package insert for a medication called MYDAYIS® manufactured by Takeda Pharmaceuticals. The text contains information such as temperature storage instructions and distribution details for the medication. Additionally, it mentions that MYDAYIS® is a registered trademark of Takeda Pharmaceuticals.*

FDA Label Image

Principal Display Panel (37.5 mg Capsule Bottle Label)

FDA Label Image

Principal Display Panel (50 mg Capsule Bottle Label)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.